Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab Concentrations in Breast Milk of Lactating Participants
NCT07612267Phase 4Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2026
- Primary completion
- Sep 2028
- Countries
- 7
01
Overview
A Phase 4 trial of mirikizumab in inflammatory bowel disease (IBD), sponsored by Eli Lilly and Company. Started Aug 2026; status: recruiting.
02
Drugs
mirikizumab
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT07612267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07612267.